Vaxcyte (NASDAQ:PCVX) Releases Earnings Results

Vaxcyte (NASDAQ:PCVX) issued its earnings results on Wednesday. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28, Briefing.com reports.

Vaxcyte Price Performance

Shares of PCVX stock traded down $1.26 on Thursday, hitting $65.53. 241,053 shares of the company’s stock were exchanged, compared to its average volume of 806,012. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $82.04. The company has a 50 day moving average of $66.14 and a 200 day moving average of $62.45. The stock has a market cap of $7.10 billion, a P/E ratio of -15.80 and a beta of 0.94.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $95.00 price target on shares of Vaxcyte in a research report on Thursday. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $78.50.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $69.02, for a total transaction of $552,160.00. Following the sale, the chief financial officer now owns 95,679 shares in the company, valued at approximately $6,603,764.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Grant Pickering sold 2,616 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $73.70, for a total value of $192,799.20. Following the sale, the chief executive officer now directly owns 148,670 shares of the company’s stock, valued at $10,956,979. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $69.02, for a total transaction of $552,160.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares of the company’s stock, valued at $6,603,764.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,294 shares of company stock valued at $4,254,105. Company insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.